The ANDA is held by its partner Natco Pharma Limited, India and Breckenridge plans to launch immediately. Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year ...

Susumu Hijioka, MD, discussed how a lower dose of everolimus may help address certain adverse events like oral mucositis and hypoglycemia. Dose adjustments may benefit patients with unresectable or ...

Everolimus plus lanreotide resulted in a progression-free survival of 29.7 months in patients with gastroenteropancreatic neuroendocrine tumors, compared with 11.5 months with everolimus monotherapy.

The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine ...